The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Remdesivir for the Treatment of Covid-19 — Final Report
Open accessAbstract
BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. METHODS: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. RESULTS: A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001, by a log-rank test). In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity). The Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%). CONCLUSIONS: Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hú, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,994
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,258 · cited 4×
“The trial site in South Korea received funding from the Seoul National University Hospital.”
InfluentialWang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,442
Sheahan, T. P., Sims, A. M., Leist, S. R., Schäfer, A., Won, J. J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D. M., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,757
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. M., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrć, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,575 · cited 3×
“There were 60 trial sites and 13 subsites in the United States (45 sites), Denmark (8), the United Kingdom (5), Greece (4), Germany (3), Korea (2), Mexico (2), Spain (2), Japan (1), and Singapore (1).”
Agostini, M. L., Andres, E. L., Sims, A. M., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,418
Spinner, C. D., Gottlieb, R., Criner, G. J., Arribas, J. R., Cattelan, A. M., Soriano, À., Ogbuagu, O. E., Malhotra, P., Mullane, K. M., Castagna, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.16349 · Cited by 1,234
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D. P., Cihlář, T., & Feldmann, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922083117 · Cited by 888
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,018
Kim, P. S., Read, S. W., & Fauci, A. S. (2020) · JAMA · doi:10.1001/jama.2020.22813 · Cited by 128
Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System
Peng, X., Ouyang, J., Isnard, S., Lin, J. C.-Y., Fombuena, B., Zhu, B., & Routy, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.596631 · Cited by 126
Xu, X., Jiang, W., Chen, L., Xu, Z., Zhang, Q., Zhu, M., Ye, P., Li, H., Yu, L., Zhou, X., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.297 · Cited by 122
Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection
Pérez‐Gómez, A., Vitallé, J., Gasca‐Capote, C., Gutiérrez‐Valencia, A., Trujillo‐Rodríguez, M., Serna‐Gallego, A., Muñoz‐Muela, E., Jiménez‐León, M. R., Benhnia, M. R., Rivas‐Jeremías, I., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00728-2 · Cited by 121
Wolfe, C. R., Tomashek, K. M., Patterson, T. F., Gómez, C. A., Marconi, V. C., Jain, M. K., Yang, O. O., Paules, C. I., Palacios, G. M. R., Grossberg, R. M., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00088-1 · Cited by 123
“…(nasopharyngeal swab samples could be substituted), and serum for exploratory and secondary research were collected on days 1 (before initial dosing), 3, 5, 8, and 11 while hospitalised, and on days 15 and 29 for participants who were able to attend an in-person visit or who remained hospitalised.”
Holland, T. L., Ginde, A. A., Paredes, R., Murray, T. A., Engen, N. W., Grandits, G., Vekstein, A. M., Ivey, N., Mourad, A., Sandkovsky, U., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00215-6 · Cited by 123
Manigandan, S., Wu, M., Ponnusamy, V. K., Raghavendra, V. B., Pugazhendhi, A., & Brindhadevi, K. (2020) · Process Biochemistry · doi:10.1016/j.procbio.2020.08.016 · Cited by 122
Rodríguez‐Baño, J., Pachón, J., Carratalà, J., Ryan, P., Jarrín, I., Yllescas, M., Arribas, J. R., Berenguer, J., Muñoz, E. A., Divasson, P. G., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.08.010 · Cited by 122
The COVID-19 pandemic: consequences for nephrology
Bruchfeld, A. N. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00381-4 · Cited by 127
Intensive care management of patients with COVID-19: a practical approach
Hajjar, L. A., Costa, I. B. S. D. S., Rizk, S. I., Biselli, B., Gomes, B. R., Bittar, C. S., de Oliveira, G. Q., de Almeida, J. P., Bello, M. V. D. O., Garzillo, C. L., et al. (2021) · Annals of Intensive Care · doi:10.1186/s13613-021-00820-w · Cited by 141
Inpatient Hospital Costs for COVID-19 Patients in the United States
Ohsfeldt, R. L., Choong, C., Collam, P. M., Abedtash, H., Kelton, K. A., & Burge, R. T. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01887-4 · Cited by 122
Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation
Khaitov, M. R., Nikonova, A. A., Shilovskiy, I. P., Kozhikhova, K. V., Кофиади, И. А., Vishniakova, L. I., Nikolskii, A., Gattinger, P., Kovchina, V. I., Barvinskaia, E. D., et al. (2021) · Allergy · doi:10.1111/all.14850 · Cited by 123
Neutralizing Antibody Therapeutics for COVID-19
Hurt, A. C., & Wheatley, A. K. (2021) · Viruses · doi:10.3390/v13040628 · Cited by 121
Terada, M., Ohtsu, H., Saito, S., Hayakawa, K., Tsuzuki, S., Asai, Y., Matsunaga, N., Kutsuna, S., Sugiura, W., & Ohmagari, N. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047007 · Cited by 121
Efficacy of Remdesivir in COVID-19
McCreary, E. K., & Angus, D. (2020) · JAMA · doi:10.1001/jama.2020.16337 · Cited by 121
Covid-19: Remdesivir has little or no impact on survival, WHO trial shows
Dyer, O. (2020) · BMJ · doi:10.1136/bmj.m4057 · Cited by 121
After 62 years of regulating immunity, dexamethasone meets COVID-19
Cain, D. W., & Cidlowski, J. A. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-00421-x · Cited by 120
Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019
Burwick, R. M., Yawetz, S., Stephenson, K. E., Collier, A.-R. Y., Sen, P., Blackburn, B. G., Kojic, E. M., Hirshberg, A., Suarez, J. F., Sobieszczyk, M. E., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1466 · Cited by 120
Toll-Like Receptors and COVID-19: A Two-Faced Story with an Exciting Ending
Onofrio, L., Caraglia, M., Facchini, G., Margherita, V., Placido, S. D., & Buonerba, C. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0091 · Cited by 119
Biomarkers of COVID-19 and technologies to combat SARS-CoV-2
Zhang, L., & Guo, H. (2020) · Advances in Biomarker Sciences and Technology · doi:10.1016/j.abst.2020.08.001 · Cited by 118
Aman, J., Duijvelaar, E., Botros, L., Kianzad, A., Schippers, J. R., Smeele, P. J., Azhang, S., Bartelink, I. H., Bayoumy, A. A., Bet, P. M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00237-x · Cited by 120
Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
Cox, R. M., Wolf, J. D., Lieber, C. M., Sourimant, J., Lin, M. J., Babusis, D. M., Pont, V. D., Chan, J., Barrett, K., Lye, D. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26760-4 · Cited by 119
Cesaro, S., Ljungman, P. T., Mikulska, M., Hirsch, H. H., von Lilienfeld‐Toal, M., Cordonnier, C., Meylan, S., Mehra, V., Styczyński, J., Marchesi, F., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01578-1 · Cited by 120
“However, in the main study that focused on time to recovery, comprised 80 cancer patients (8%), treatment with remdesivir did result in faster rates to recovery; the benefit was most pronounced in patients with low-flow O2 requirements and in those with less than 10 days of symptoms, consistent with its impact mainly…”
BackgroundAzithromycin for COVID-19: More Than Just an Antimicrobial?
Bleyzac, N., Goutelle, S., Bourguignon, L., & Tod, M. M. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00933-3 · Cited by 127
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report
Buckland, M. S., Galloway, J. B., Fhogartaigh, C. N., Meredith, L. W., Provine, N. M., Bloor, S., Ogbe, A., Zelek, W. M., Smielewska, A., Yakovleva, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19761-2 · Cited by 119
Dissecting lipid metabolism alterations in SARS-CoV-2
Casari, I., Manfredi, M., Metharom, P., & Falasca, M. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101092 · Cited by 120
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Zhou, Y., Xie, Y., Tang, L., Pu, D., Zhu, Y., Liu, J., & Ma, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00733-x · Cited by 116
Mozaffari, E., Chandak, A. N., Zhang, Z., Liang, S., Thrun, M. W., Gottlieb, R., Kuritzkes, D. R., Sax, P. E., Wohl, D. A., Casciano, R., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab875 · Cited by 123
Zhang, G., Cong, Y., Liu, F., Sun, J., Zhang, J., Cao, G., Zhou, L., Yang, W., Song, Q., Wang, F., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01177-2 · Cited by 120
Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2
Renn, A., Fu, Y., Hu, X., Hall, M. D., & Simeonov, A. M. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.07.004 · Cited by 117
Yousefi, H., Mashouri, L., Okpechi, S. C., Alahari, N. V., & Alahari, S. K. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114296 · Cited by 117
Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19
Cui, W., Yang, K., & Yang, H. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.616341 · Cited by 117
Synergistic and Antagonistic Drug Combinations against SARS-CoV-2
Bobrowski, T., Chen, L., Eastman, R. T., Itkin, Z., Shinn, P., Chen, C. Z., Guo, H., Zheng, W., Michael, S., Simeonov, A. M., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.016 · Cited by 119
Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials
Vegivinti, C. T. R., Evanson, K. W., Lyons, H., Akosman, I., Barrett, A., Hardy, N. J., Kane, B., Keesari, P. R., Pulakurthi, Y. S., Sheffels, E., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07068-0 · Cited by 119
Navas, P., Amor, A. M., Crespo, M., Wolowiec, Z., & Alonso, M. Á. V. (2020) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2020.103813 · Cited by 116
Brendler, T., Al‐Harrasi, A., Bauer, R., Gafner, S., Hardy, M. L., Heinrich, M., Hosseinzadeh, H., Izzo, A. A., Michaelis, M., Nassiri‐Asl, M., et al. (2020) · Phytotherapy Research · doi:10.1002/ptr.7008 · Cited by 122
Ohl, M., Miller, D. R., Lund, B. C., Kobayashi, T., Miell, K. R., Beck, B. F., ALEXANDER, B. K., Crothers, K. A., & Vaughan‐Sarrazin, M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.14741 · Cited by 116
Barratt‐Due, A., Olsen, I. C., Henriksen, K. N., Kåsine, T., Lund‐Johansen, F., Hoel, H., Holten, A. R., Tveita, A. A., Mathiessen, A., Haugli, M., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0653 · Cited by 121
Remdesivir for severe covid-19: a clinical practice guideline
Rochwerg, B. N., Agarwal, A., Zeng, L., Leo, Y., Appiah, J. A., Agoritsas, T., Bartoszko, J. J., Brignardello‐Petersen, R., Ergan, B., Ge, L., et al. (2020) · BMJ · doi:10.1136/bmj.m2924 · Cited by 117
Fiege, J. K., Thiede, J. M., Nanda, H. A., Matchett, W. E., Moore, P. J., Montanari, N. R., Thielen, B. K., Daniel, J. J., Stanley, E., Hunter, R. C., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009292 · Cited by 108
Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2
Esposito, S., & Principi, N. (2021) · Pediatric Drugs · doi:10.1007/s40272-020-00435-x · Cited by 122
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
Mengist, H. M., Kombe, A. J. K., Mekonnen, D. S., Abebaw, A., Getachew, M., & Jin, T. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101533 · Cited by 115
Small molecules in the treatment of COVID-19
Lei, S., Chen, X., Wu, J., Duan, X., & Men, K. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01249-8 · Cited by 119
“first reported its clinical application, which described an immediate improvement in clinical symptoms in the first confirmed case of SARS-CoV-2 after receiving remdesivir administration.(276,277) However, according to a recent study conducted by Stevens et al.”
ResultAnsarin, K., Tolouian, R., Ardalan, M., Taghizadieh, A., Varshochi, M., Teimouri, S., Vaezi, T., Valizadeh, H., Saleh, P., Safiri, S., et al. (2020) · Bioimpacts · doi:10.34172/bi.2020.27 · Cited by 115
Godman, B., Haque, M., Islam, S., Iqbal, S., Urmi, U. L., Kamal, Z. M., Shuvo, S. N., Rahman, A., Kamal, M., Haque, M., et al. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.585832 · Cited by 114
AlQahtani, M., Abdulrahman, A., Almadani, A. H., AlAli, S., Alzamrooni, A. M., Hejab, A. H., Conroy, R. M., Wasif, P., Otoom, S. A.-A., Atkin, S. L., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89444-5 · Cited by 114
Post-COVID-19 Pulmonary Fibrosis: Novel Sequelae of the Current Pandemic
Ambardar, S., Hightower, S. L., Huprikar, N., Chung, K. K., SINGHAL, A. L., & Collen, J. F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112452 · Cited by 120
Sabaka, P., Koščálová, A., Straka, I., Hodosy, J., Lipták, R., Kmotorková, B., Kachlíková, M., & Kušnírová, A. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05945-8 · Cited by 130
Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties
Matthay, M. A., & Thompson, B. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30503-8 · Cited by 124
Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns
Touafchia, A., Bagheri, H., Carrié, D., Durrieu, G., Sommet, A., Chouchana, L., & Montastruc, F. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.02.013 · Cited by 113
Schloer, S., Brunotte, L., Mecate‐Zambrano, A., Zheng, S., Tang, J. P., Ludwig, S., & Rescher, U. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15418 · Cited by 113
Vallejos, J. A., Zoni, R., Bangher, M. D. C., Villamandos, S., Bobadilla, A., Plano, F., Campias, C., Campias, E. C., Medina, M. F., Achinelli, F., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06348-5 · Cited by 113
COVID-19 and Tuberculosis Coinfection: An Overview of Case Reports/Case Series and Meta-Analysis
Song, W.-M., Zhao, J., Zhang, Q., Liu, S., Zhu, X., An, Q.-Q., Xu, T., Li, S.-J., Liu, J., Tao, N., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.657006 · Cited by 113
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19
Eslami, G., Mousaviasl, S., Radmanesh, E., Jelvay, S., Bitaraf, S., Simmons, B., Wentzel, H., Hill, A. M., Sadeghı, A., Freeman, J. A., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa331 · Cited by 112
Xia, Z., Sacco, M. D., Hu, Y., Ma, C., Meng, X., Zhang, F., Szeto, T., Xiang, Y., Chen, Y., & Wang, J. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00099 · Cited by 112
Contraception and reproductive planning during the COVID-19 pandemic
Filho, E. S. F., de Melo, N. R., Sorpreso, I. C. E., Bahamondes, L. G., Simões, R. S., Soares, J. M., & Baracat, E. C. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1782738 · Cited by 111
Pathogenesis, Clinical Manifestations and Complications of COVID-19
Kordzadeh-Kermani, E., Khalili, H., & Karimzadeh, I. (2020) · Future Microbiology · doi:10.2217/fmb-2020-0110 · Cited by 121
Martinot, M., Jary, A., Fafi‐Kremer, S., Leducq, V., Delagreverie, H. M., Garnier, M., Pacanowski, J., MEKINIAN, A., Pirenne, F., Tiberghien, P., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1474 · Cited by 111
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review
Cantini, F., Goletti, D., Petrone, L., Fard, S. N., Niccoli, L., & Foti, R. (2020) · Drugs · doi:10.1007/s40265-020-01421-w · Cited by 112
Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects
Lisco, G., Tullio, A. D., Jirillo, E., Giagulli, V. A., Pergola, G. D., Guastamacchia, E., & Triggiani, V. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01554-z · Cited by 119
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context
Angriman, F., Ferreyro, B. L., Burry, L. D., Fan, E., Ferguson, N. D., Husain, S., Keshavjee, S. H., Lupia, E., Munshi, L., Renzi, S., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00139-9 · Cited by 119
Acute Respiratory Distress Syndrome
Williams, G. W., Berg, N. K., Reskallah, A., Yuan, X., & Eltzschig, H. K. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003571 · Cited by 123
Toussi, S. S., Hammond, J., Gerstenberger, B. S., & Anderson, A. S. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01356-4 · Cited by 113
COVID-19: from epidemiology to treatment
Pericàs, J. M., Meneses, M. H., Sheahan, T. P., Quintana, E., Ambrosioni, J., Sandoval, E., Falces, C., Marcos, M. Á., Tuset, M., Vilella, A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa462 · Cited by 110
Treatment Options for COVID-19: A Review
Ali, M. J., Hanif, M., Haider, M. A., Ahmed, M. U., Sundas, F., Hirani, A., Khan, I. A., Anis, K., & Karim, A. H. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00480 · Cited by 108
Remdesivir for the treatment of COVID-19
Grundeis, F., Ansems, K., Dahms, K., Thieme, V., Metzendorf, M., Skoetz, N., Benstoem, C., Mikołajewska, A., Griesel, M., Fichtner, F., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014962.pub2 · Cited by 112
Is hydroxychloroquine beneficial for COVID-19 patients?
Li, X., Wang, Y., Agostinis, P., Rabson, A. B., Melino, G., Carafoli, E., Shi, Y., & Sun, E. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2721-8 · Cited by 111
Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study
Alcala-Diaz, J. F., Pérez, L. L., Gómez‐Huelgas, R., Escalante, M. D. M., Rodríguez, B. C., Zambrana-García, J. L., Castillo, M. E., Pérez-Caballero, A. I., Lopez-Carmona, M. D., García‐Alegría, J., et al. (2021) · Nutrients · doi:10.3390/nu13061760 · Cited by 112
Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial
Mahmud, R., Rahman, M. M., Alam, I., Ahmed, K. G. U., Kabir, A., Sayeed, S. K. J. B., Rassel, M. A., Monayem, F. B., Islam, M. S., Islam, M. M., et al. (2021) · Journal of International Medical Research · doi:10.1177/03000605211013550 · Cited by 108
An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines
Hillary, V. E., & Ceasar, S. A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13952 · Cited by 121
“This result revealed that remdesivir reduced the recovery time from 15 days to 11 days in hospitalized SARS-CoV-2 infected patients [62].”
Chen, C. Z., Xu, M., Pradhan, M., Gorshkov, K., Petersen, J. D., Straus, M. R., Zhu, W., Shinn, P., Guo, H., Shen, M., et al. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00112 · Cited by 106
Shohan, M., Nashibi, R., Mahmoudian‐Sani, M., Abolnezhadian, F., Ghafourian, M., Alavi, S. M., Sharhani, A., & Khodadadi, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174615 · Cited by 114
TheStaphylococcus aureusNetwork Adaptive Platform Trial Protocol: New Tools for an Old Foe
Tong, S. Y. C., Mora, J. M., Bowen, A. C., Cheng, M. P., Daneman, N., Goodman, A. L., Heriot, G., Lee, T. C., Lewis, R. J., Lye, D. C., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac476 · Cited by 106
Spivak, M., Stone, J. E., Ribeiro, J. V., Saam, J., Freddolino, L., Bernardi, R. C., & Tajkhorshid, E. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00658 · Cited by 113
Network medicine framework for identifying drug-repurposing opportunities for COVID-19
Morselli Gysi, D., do Valle, Í., Zitnik, M., Ameli, A., Gan, X., Varol, O., Ghiassian, S. D., Patten, J. J., Davey, R. A., Loscalzo, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025581118 · Cited by 107
Seaton, R. A., Gibbons, C., Cooper, L., Malcolm, W., McKinney, R., Dundas, S., Griffith, D. M., Jeffreys, D., Hamilton, K., Choo‐Kang, B., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.09.024 · Cited by 107
Immunological memory to SARS-CoV-2 assessed for up to eight months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2020) · eScholarship (California Digital Library) · Cited by 121
The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19
Attiq, A., Yao, L. J., Afzal, S., & Khan, M. A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108255 · Cited by 111
Savela, E. S., Winnett, A. V., Romano, A. E., Porter, M. K., Shelby, N., Akana, R., Ji, J., Cooper, M. M., Schlenker, N. W., Reyes, J. A., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01785-21 · Cited by 112
Kung, Y.-A., Chiang, H.-J., Li, M.-L., Gong, Y.-N., Chiu, H.-P., Hung, C.-T., Huang, P.-N., Huang, S.-Y., Wang, P.-Y., Hsu, T.-A., et al. (2022) · mBio · doi:10.1128/mbio.02717-21 · Cited by 107
Chiotos, K., Hayes, M., Kimberlin, D. W., Jones, S. B., James, S. H., Pinninti, S. G., Yarbrough, A. H., Abzug, M. J., MacBrayne, C. E., Soma, V. L., et al. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa115 · Cited by 111
Sex Differences in Respiratory Viral Pathogenesis and Treatments
Ursin, R. L., & Klein, S. L. (2021) · Annual Review of Virology · doi:10.1146/annurev-virology-091919-092720 · Cited by 109
SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19
Fiscon, G., Conte, F., Farina, L., & Paci, P. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008686 · Cited by 108
Miller, J. M., Bruen, C. A., Schnaus, M. J., Zhang, J., Ali, S., Lind, A., Stoecker, Z. R., Stauderman, K. A., & Hebbar, S. (2020) · Critical Care · doi:10.1186/s13054-020-03220-x · Cited by 118
Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19
Faheem, F., Kumar, B. K., Sekhar, K. V. G. C., Kunjiappan, S., Jamalis, J., Balaña‐Fouce, R., Tekwani, B. L., & Murugesan, S. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104269 · Cited by 103
COVID-19 Compared to Other Pandemic Diseases
Pitlik, S. D. (2020) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10418 · Cited by 100
Nab, L., Parker, E. P. K., Andrews, C. D., Hulme, W. J., Fisher, L., Morley, J., Mehrkar, A., MacKenna, B., Inglesby, P., Morton, C. E., et al. (2023) · The Lancet Public Health · doi:10.1016/s2468-2667(23)00079-8 · Cited by 97
Artese, A., Svicher, V., Costa, G., Salpini, R., Maio, V. C. D., Alkhatib, M., Ambrosio, F. A., Santoro, M. M., Assaraf, Y. G., Alcaro, S., et al. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100721 · Cited by 103
Elsawah, H. K., Elsokary, M. A., Abdallah, M. S., & Elshafie, A. H. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2187 · Cited by 109
Development of vaccines and antivirals for combating viral pandemics
Pardi, N., & Weissman, D. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00658-w · Cited by 108
COVID-19 Diagnostics, Tools, and Prevention
Allam, M., Cai, S., Ganesh, S., Venkatesan, M., Doodhwala, S., Song, Z., Hu, T., Kumar, A., Heit, J. J., COVID- Study Group, et al. (2020) · Diagnostics · doi:10.3390/diagnostics10060409 · Cited by 105
Krüger, J., Groß, R. M., Conzelmann, C., Müller, J. A., Koepke, L., Sparrer, K. M. J., Weil, T., Schütz, D., Seufferlein, T. T. W., Barth, T. F. E., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.11.003 · Cited by 109
Pei, R., Feng, J., Zhang, Y., Sun, H., Li, L., Yang, X., He, J., Xiao, S., Xiong, J., Lin, Y., et al. (2020) · Protein & Cell · doi:10.1007/s13238-020-00811-w · Cited by 107
Strich, J. R., Ramos-Benítez, M. J., Randazzo, D., Stein, S. R., Babyak, A. L., Davey, R. T., Suffredini, A. F., Childs, R. W., & Chertow, D. S. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa789 · Cited by 99
Tao, K., Tzou, P. L., Nouhin, J., Bonilla, H. F., Jagannathan, P., & Shafer, R. W. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00109-21 · Cited by 109
Yosri, N., El‐Wahed, A. A. A., Ghonaim, R., Khattab, O. M., Sabry, A., Ibrahim, M. A. A., Moustafa, M., Guo, Z., Zou, X., Algethami, A. F. M., et al. (2021) · Foods · doi:10.3390/foods10081776 · Cited by 105
Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals
Meekins, D. A., Gaudreault, N. N., & Richt, J. A. (2021) · Viruses · doi:10.3390/v13101993 · Cited by 105
van Vuren, E. J., Steyn, S. F., Brink, C. B., Möller, M., Viljoen, F. P., & Harvey, B. H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111200 · Cited by 106
Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis
Rezagholizadeh, A., Khiali, S., Sarbakhsh, P., & Entezari‐Maleki, T. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173926 · Cited by 103
Benchmark of Popular Free Energy Approaches Revealing the Inhibitors Binding to SARS-CoV-2 Mpro
Ngô, S. T., Tâm, N. M., Quân, P. M., & Nguyen, T. H. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00159 · Cited by 101
Metadata
- Authors
- Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., Touloumi, G., Lye, D. C., Ohmagari, N., Oh, M.-D., Ruiz-Palacios, G. M., Benfield, T., Fätkenheuer, G., Kortepeter, M. G., Atmar, R. L., Creech, C. B., Lundgren, J., Babiker, A. G., Pett, S., Neaton, J. D., Burgess, T. H., Bonnett, T., Green, M., Makowski, M., Osinusi, A., Nayak, S., & Lane, H. C.
- Affiliations
- National Institutes of Health (US)
- From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) — all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical...
- Corresponding author
- Beigel, John H.
- ORCID
- Beigel, John H.
- Dodd, Lori E.
- Mehta, Aneesh K.
- Zingman, Barry S.
- Kalil, Andre C.
- Hohmann, Elizabeth
- Chu, Helen Y.
- Luetkemeyer, Annie
- Kline, Susan
- Finberg, Robert W.
- Dierberg, Kerry
- Tapson, Victor
- Patterson, Thomas F.
- Paredes, Roger
- Short, William R.
- Touloumi, Giota
- Lye, David Chien
- Ohmagari, Norio
- Oh, Myoung-don
- Ruiz-Palacios, Guillermo M.
- Benfield, Thomas
- Fätkenheuer, Gerd
- Atmar, Robert L.
- Creech, C. Buddy
- Lundgren, Jens
- Babiker, Abdel G.
- Pett, Sarah
- Neaton, James D.
- Burgess, Timothy H.
- Bonnett, Tyler
- Makowski, Mat
- Nayak, Seema
- Lane, H. Clifford
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-11-05
- Volume
- 383
- Issue
- 19
- Pages
- 1813-1826
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7262788
- OpenAlex
- W3027630905
- Cited by
- 7,267
- References
- 22
- Citations by year
- 2026: 146 · 2025: 324 · 2024: 518 · 2023: 901 · 2022: 1447 · 2021: 2475 · 2020: 1451
- FWCI
- 206.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Figshare (submittedVersion, cc-by)
- Sussex Research Online (University of Sussex) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- eScholarship@McGill (McGill) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- Funders
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- National Cancer Institute (HHSN261200800001E, HHSN261201500003I)
- National Institute of Allergy and Infectious Diseases (UM1AI148450, UM1AI148452, UM1AI148573, UM1AI148575, UM1AI148576, UM1AI148684, UM1AI148685, UM1AI148689)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
- Keywords
- remdesivir, COVID-19 pandemic, SARS-CoV-2, antiviral therapy, hospitalized patients, lower respiratory tract infection, time to recovery, mortality, serious adverse events, clinical improvement, treatment efficacy, SARS-CoV-2 RNA load, viral load reduction, disease severity, prognostic factors, prognostic score
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Adenosine Monophosphate, Adult, Aged, Alanine, Antiviral Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Oxygen Inhalation Therapy, Pneumonia, Viral, Respiration, Artificial, Time Factors, Extracorporeal Membrane Oxygenation, Coronavirus Infections, Kaplan-Meier Estimate, Young Adult, Pandemics, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
